RxDoctor Payments Data

Omolara Kuteyi, MD

Family Medicine · Decatur, GANPI 1780648568

Payments from drug & device makers

$1,843in general payments, 2019–2025

Across 74 payments — averaging $24.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$771
  • Shield Therapeutics Inc$158
  • Lilly USA, LLC$137
  • AstraZeneca$104
  • Boehringer Ingelheim$93
  • Urovant Sciences Inc$84
  • plus $495 from 15 others

What the payments were for

  • Food & beverage$1,843100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,843 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$23,567
Medicare patients
46
Services billed
301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala12$47,347
EliquisApixaban41$12,273
JardianceEmpagliflozin15$4,267
EntrestoSacubitril/Valsartan13$4,085
JanuviaSitagliptin Phosphate14$3,750
NovologInsulin Aspart30$2,366
Atorvastatin Calcium184$2,324
Galantamine Hbr20$1,934
Mirtazapine26$1,467
Donepezil Hcl38$1,380
Gabapentin69$1,356
Insulin Lispro Kwikpen U-100Insulin Lispro11$1,339
Amlodipine Besylate143$1,263
Carvedilol77$1,246
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$12,27341 claims
Boehringer IngelheimJardiance$93$4,26715 claims
NovartisEntresto$17$4,08513 claims
Novo NordiskNovolog$60$2,36630 claims
Sanofi-aventis U.S. LLCLantus$27$1,09015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →